Randomized Phase II Trial of Sapanisertib ± TAK-117 vs. Everolimus in Patients With Advanced Renal Cell Carcinoma After VEGF-Targeted Therapy.

Oncologist · 2022 · PMC9732228 · PMID 36146944

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In all 3 treatment arms, patients showed a trend for deterioration from baseline in HRQoL and disease-related symptoms, as indicated by the mean change from baseline in EORTC QLQ-C30 ( Supplementary Fig.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.